We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App





Siemens Presents Latest Innovations and Trends in Clinical Diagnostics and POC Testing

By LabMedica International staff writers
Posted on 21 May 2023

Siemens Healthineers (Erlangen, Germany) is presenting its newest innovations at WorldLab–EuroMedLab Roma 2023 that aim to help deliver high-value care, and confidently provide the answers expected by clinicians and patients. More...

A team of company experts is demonstrating innovations and trends in clinical diagnostics and point-of-care testing at the industry event.

On display at the Siemens booth are the company’s two new solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. Both hematology analyzers offer integrated automation and intelligence to eliminate barriers that hamper workflow efficiency and deliver faster patient results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers have a throughput of up to 120 tests per hour and feature user-friendly designs that significantly reduce time-consuming daily maintenance and support rapid reagent changes.

The Atellica HEMA 570 and Atellica HEMA 580 Analyzers adopt advanced data management capabilities to eliminate the expertise gap and empower staff of all skill levels during result interpretations. In order to save time and provide physicians with information more quickly, normal results that do not violate pre-established criteria are released directly into a laboratory information system using the analyzers' rules-based auto-validation capability. Abnormalities are flagged and coded on the basis of severity to provide a clear indication of which patient samples need closer attention from the technician. In case results require follow-up actions like dilutions or slide reviews, standardized guidance is displayed to ensure that staff performs the next steps in accordance with lab protocols.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.